Format

Send to

Choose Destination
J Neurooncol. 2012 Apr;107(2):225-32. doi: 10.1007/s11060-011-0739-6. Epub 2011 Oct 26.

Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation.

Author information

1
Divisions of Hematology-Oncology, and Hematopathology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, 5150 Center Ave., Suite. 572, Pittsburgh, PA 15232, USA.

Abstract

Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after allogeneic hematopoietic stem cell transplantation (HSCT). Extra nodal involvement is common in PTLD, but isolated involvement of the central nervous system (CNS) is extremely rare. Given the rarity of primary CNS-PTLD there is no consensus on optimal treatment. We report a patient who developed Epstein-Barr virus related primary CNS-PTLD following allogeneic HSCT who was treated with the monoclonal anti-CD20 antibody rituximab and reduction of immunosuppression. In addition, we review the literature and discuss treatment options for patients with primary CNS-PTLD following allogeneic HSCT.

PMID:
22037801
DOI:
10.1007/s11060-011-0739-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center